5-氯-4-硝基噻吩-2-羧酸甲酯 | 57800-76-7

• 物质功能分类: 医药中间体 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-氯-4-硝基噻吩-2-羧酸甲酯
• 中文别名: 4-硝基-5-氯噻吩-2-甲酸甲酯
• 英文名称: methyl 5-chloro-4-nitrothiophene-2-carboxylate
• 英文别名: 5-chloro-4-nitrothiophene-2-carboxylic acid methyl ester
• CAS: 57800-76-7
• 化学式: C₆H₄ClNO₄S
• mdl: MFCD08275718
• 分子量: 221.621
• InChiKey: IJSXVHIIYIMVTM-UHFFFAOYSA-N

物化性质

• 熔点：
  83-84 °C
• 沸点：
  349.3±37.0 °C(Predicted)
• 密度：
  1.576±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  100
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Chloro-5-methylpyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-5-methylpyridine
CAS number: 19230-55-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6ClN
Molecular weight: 127.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-4-硝基噻吩-2-羧酸甲酯 在 potassium carbonate 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 1.0h， 生成 4-硝基-5-(BOC-氨基)噻吩-2-甲酸甲酯
  参考文献：
  名称：

  THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS

  摘要：

  该发明涉及通式（I）所示化合物或其药学上可接受的盐。这些化合物可用于治疗癌症。

  公开号：

  US20130079341A1
• 作为产物：
  描述：

  5-氯噻吩-2-甲酸甲酯 在 硫酸 、 硝酸 作用下， 反应 3.0h， 以47.8%的产率得到5-氯-4-硝基噻吩-2-羧酸甲酯
  参考文献：
  名称：

  发现3-（噻吩/噻唑-2-基硫基）吡啶衍生物作为多靶点抗癌药

  摘要：

  设计并合成了一系列新颖的3-（噻吩/噻唑-2-基硫基）吡啶衍生物，作为IGF-1R酪氨酸激酶抑制剂。测试了所有目标化合物对五种癌细胞系（K562，Hep-G2，HCT-116，WSU-DLCL2和A549）的IGF-1R激酶抑制活性和细胞毒性。尽管所有这些化合物均表现出中度至有效的癌细胞增殖抑制活性（最有效的化合物43的IC 50为50对WSU-DLCL2细胞系的检测值为1.3±0.9μM），未观察到IGF-1R抑制作用。为了鉴定这些类似物的确切靶标，进一步筛选了所选化合物的各种激酶。结果表明该系列化合物可通过抑制各种激酶（包括FGFR 3，EGFR，JAK和RON）发挥其抗癌活性。此外，化合物43在Hep-G2细胞上的细胞周期分析显示，细胞周期停滞在G1 / G0期。所有实验都验证了3-（噻吩/噻唑-2-基硫基）吡啶类似物作为多靶点抗癌药的潜力。

  DOI：

  10.1007/s00044-019-02400-x

文献信息

• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2009137499A1

  公开（公告）日：2009-11-12

  Compounds which are histone deacetylase inhibitors and their use in treating various disorders, including Alzheimer's Disease.

  组合物是组蛋白去乙酰化酶抑制剂，用于治疗各种疾病，包括阿尔茨海默病。
• [EN] THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS<br/>[FR] COMPOSÉS THIÉNO(2,3B)PYRAZINE EN TANT QU'INHIBITEURS DE B-RAF
  申请人：ORGANON NV

  公开号：WO2011147764A1

  公开（公告）日：2011-12-01

  The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.

  该发明涉及符合一般式（I）或其药学上可接受的盐的化合物。这些化合物可用于治疗癌症。
• 一种新的ASK1抑制剂及其应用
  申请人：山东轩竹医药科技有限公司

  公开号：CN110294746B

  公开（公告）日：2023-01-31

  本发明涉及通式(I)所示的化合物、其药学上可接受的盐、酯或其立体异构体。本发明还涉及该化合物的制备方法、包含该化合物的药物制剂及药物组合物。本发明的化合物能够有效抑制ASK1的氨基酸磷酸化，抑制ASK1的激活；因此能够治疗和/或预防ASK1介导的疾病及相关疾病。
• [EN] ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS<br/>[FR] COMPOSÉS ANTINÉOPLASIQUES, COMPOSITIONS ET PROCÉDÉS
  申请人：PROGENRA INC

  公开号：WO2010114881A1

  公开（公告）日：2010-10-07

  Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.

  公开的是新型化合物，这些化合物在治疗上具有用途，特别是在抗肿瘤治疗和其他涉及半胱氨酸蛋白酶抑制的治疗方案中。